Results 131 to 140 of about 1,577 (196)

Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. [PDF]

J Immunother Cancer
Melero I, Steeghs N, Lassen U, Homicsko K, Tabernero J, Cañamero M, Roller A, Duarte J, Rossmann E, Babitzki G, Grabole N, Watson C, Habigt C, Evers S, Dejardin D, Teichgräber V, Charo J.   +16 more
europepmc   +1 more source

DI-Leu16-IL2 Immunocytokine [PDF]

, 2020
openaire   +1 more source

TNF-α x FcαRI bi-specific antibody potentiates neutrophil-mediated anti-tumor effects. [PDF]

Sci Rep
Gout DY, Sewnath CAN, Duru G, van der Mast R, Tuk CW, Bentlage AEH, Gruijs M, Vidarsson G, Heemskerk N, van Egmond M.   +9 more
europepmc   +1 more source

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors. [PDF]

ESMO Open
Lassen U, van Brummelen EMJ, Melero I, Angevin E, Joensuu H, Segal NH, Mau-Sørensen M, Steeghs N, Rodríguez-Ruiz ME, Homicsko K, Tabernero J, Cañamero M, Dejardin D, Habigt C, Rossmann E, Guarin E, Babitzki G, Baumann HES, Silva AP, Adessi C, Boetsch C, Evers S, Charo J, Teichgräber V, Argilés G.   +24 more
europepmc   +1 more source

Advancements and challenges in immunocytokines: A new arsenal against cancer. [PDF]

Acta Pharm Sin B
Shi W, Liu N, Lu H.
europepmc   +1 more source

PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer. [PDF]

JCI Insight
Pratumchai I, Bernardo M, Tessier J, Zak J, Marquardt KL, Lee JS, Bimal M, Choi A, Byers AM, Devonish MG, Carrio R, Lu D, Martomo S, Patel J, Zhang YA, Langohr IM, Cortez-Retamozo V, Bangari DS, Hadjipanayis A, Li X, Fantin VR, Shaffer DR, Teijaro JR.   +22 more
europepmc   +1 more source

Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors. [PDF]

Clin Cancer Res
Melero I, Tabernero J, Steeghs N, Robbrecht DGJ, Peters S, Rizvi NA, O'Reilly EM, Calvo E, Eefsen RL, Leighl N, Cervantes A, Hafez N, Habigt C, Andersson E, Dejardin D, Rossmann E, Martinez Quetglas I, Babitzki G, Duarte J, Adessi C, Boetsch C, Evers S, Charo J, Teichgräber V, Lassen U.   +24 more
europepmc   +1 more source

Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor. [PDF]

Front Immunol
Gao H, Ma T, Jiang Q, Gao L, Li J, Wang S, Liu Z, Zhang Z, Wu G, He W, Zhou F.   +10 more
europepmc   +1 more source

Non-neuronal cholinergic stimulation favors bone mass accrual. [PDF]

Front Physiol
Tamimi F, Eimar H, Alebrahim S, Abu-Nada L, Manickam G, Al Subaie AE, Tamimi I, Murshed M.   +7 more
europepmc   +1 more source

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies. [PDF]

Vaccines (Basel)
Balkhi S, Bilato G, De Lerma Barbaro A, Orecchia P, Poggi A, Mortara L.   +5 more
europepmc   +1 more source